Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid Leukemia and complex cytogenetics

Aziz Nazha, Hagop M. Kantarjian, Vijaya R. Bhatt, Graciela Nogueras-Gonzalez, Jorge E. Cortes, Tapan Kadia, Guillermo Garcia-Manero, Lynne Abruzzo, Naval Daver, Naveen Pemmaraju, Alfonso Quintas-Cardama, Farhad Ravandi, Michael Keating, Gautam Borthakur

Research output: Contribution to journalArticle

Abstract

Background Chromosome 17 abnormalities are associated with poor outcome in leukemias including AML. Recently, MK was introduced as an independent predictor of dismal outcome in AML. The additional prognostic effect of C17 abns in patients with MK in a CK background is not clear. Patients and Methods We conducted a retrospective analysis of 1086 patients with newly diagnosed AML treated between January 1998 and December 2007. Patients received treatment with one of the institution's first-line protocols. Results Four hundred eighty-three patients had CK. Among them, 370 patients (77%) had CK-MK, and 195 patients (53%) had CK-MK-C17 abns. Patients with CK-MK had significantly shorter OS rates compared with patients with CK without MK (4.4 vs. 8 months, respectively; P =.002). The median OS for patients with CK-C17 abns was shorter than for patients without C17 abns (4 vs. 6.1 months, respectively; P =.004). In a multivariate analysis, the presence of MK among patients with CK was identified as an independent prognostic marker for OS. In addition, presence of C17 abns had a significant negative effect on OS among patients with CK-MK (P =.04). Conclusion Among patients with CK-AML, MK was associated with poor outcomes. Additional presence of C17 abns further worsens the outcome in these particularly poor-risk patients with AML.

Original languageEnglish (US)
Pages (from-to)163-171
Number of pages9
JournalClinical Lymphoma, Myeloma and Leukemia
Volume14
Issue number2
DOIs
StatePublished - Apr 2014
Externally publishedYes

Fingerprint

Chromosomes, Human, Pair 17
Karyotype
Acute Myeloid Leukemia
Cytogenetics
Chromosome Aberrations

Keywords

  • AML
  • Chromosome 17 abnormalities
  • Complex karyotype
  • Monosomal karyotype

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid Leukemia and complex cytogenetics. / Nazha, Aziz; Kantarjian, Hagop M.; Bhatt, Vijaya R.; Nogueras-Gonzalez, Graciela; Cortes, Jorge E.; Kadia, Tapan; Garcia-Manero, Guillermo; Abruzzo, Lynne; Daver, Naval; Pemmaraju, Naveen; Quintas-Cardama, Alfonso; Ravandi, Farhad; Keating, Michael; Borthakur, Gautam.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 14, No. 2, 04.2014, p. 163-171.

Research output: Contribution to journalArticle

Nazha, A, Kantarjian, HM, Bhatt, VR, Nogueras-Gonzalez, G, Cortes, JE, Kadia, T, Garcia-Manero, G, Abruzzo, L, Daver, N, Pemmaraju, N, Quintas-Cardama, A, Ravandi, F, Keating, M & Borthakur, G 2014, 'Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid Leukemia and complex cytogenetics', Clinical Lymphoma, Myeloma and Leukemia, vol. 14, no. 2, pp. 163-171. https://doi.org/10.1016/j.clml.2013.07.009
Nazha, Aziz ; Kantarjian, Hagop M. ; Bhatt, Vijaya R. ; Nogueras-Gonzalez, Graciela ; Cortes, Jorge E. ; Kadia, Tapan ; Garcia-Manero, Guillermo ; Abruzzo, Lynne ; Daver, Naval ; Pemmaraju, Naveen ; Quintas-Cardama, Alfonso ; Ravandi, Farhad ; Keating, Michael ; Borthakur, Gautam. / Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid Leukemia and complex cytogenetics. In: Clinical Lymphoma, Myeloma and Leukemia. 2014 ; Vol. 14, No. 2. pp. 163-171.
@article{496d0c26504846349ff0d94b02b831f5,
title = "Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid Leukemia and complex cytogenetics",
abstract = "Background Chromosome 17 abnormalities are associated with poor outcome in leukemias including AML. Recently, MK was introduced as an independent predictor of dismal outcome in AML. The additional prognostic effect of C17 abns in patients with MK in a CK background is not clear. Patients and Methods We conducted a retrospective analysis of 1086 patients with newly diagnosed AML treated between January 1998 and December 2007. Patients received treatment with one of the institution's first-line protocols. Results Four hundred eighty-three patients had CK. Among them, 370 patients (77{\%}) had CK-MK, and 195 patients (53{\%}) had CK-MK-C17 abns. Patients with CK-MK had significantly shorter OS rates compared with patients with CK without MK (4.4 vs. 8 months, respectively; P =.002). The median OS for patients with CK-C17 abns was shorter than for patients without C17 abns (4 vs. 6.1 months, respectively; P =.004). In a multivariate analysis, the presence of MK among patients with CK was identified as an independent prognostic marker for OS. In addition, presence of C17 abns had a significant negative effect on OS among patients with CK-MK (P =.04). Conclusion Among patients with CK-AML, MK was associated with poor outcomes. Additional presence of C17 abns further worsens the outcome in these particularly poor-risk patients with AML.",
keywords = "AML, Chromosome 17 abnormalities, Complex karyotype, Monosomal karyotype",
author = "Aziz Nazha and Kantarjian, {Hagop M.} and Bhatt, {Vijaya R.} and Graciela Nogueras-Gonzalez and Cortes, {Jorge E.} and Tapan Kadia and Guillermo Garcia-Manero and Lynne Abruzzo and Naval Daver and Naveen Pemmaraju and Alfonso Quintas-Cardama and Farhad Ravandi and Michael Keating and Gautam Borthakur",
year = "2014",
month = "4",
doi = "10.1016/j.clml.2013.07.009",
language = "English (US)",
volume = "14",
pages = "163--171",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "2",

}

TY - JOUR

T1 - Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid Leukemia and complex cytogenetics

AU - Nazha, Aziz

AU - Kantarjian, Hagop M.

AU - Bhatt, Vijaya R.

AU - Nogueras-Gonzalez, Graciela

AU - Cortes, Jorge E.

AU - Kadia, Tapan

AU - Garcia-Manero, Guillermo

AU - Abruzzo, Lynne

AU - Daver, Naval

AU - Pemmaraju, Naveen

AU - Quintas-Cardama, Alfonso

AU - Ravandi, Farhad

AU - Keating, Michael

AU - Borthakur, Gautam

PY - 2014/4

Y1 - 2014/4

N2 - Background Chromosome 17 abnormalities are associated with poor outcome in leukemias including AML. Recently, MK was introduced as an independent predictor of dismal outcome in AML. The additional prognostic effect of C17 abns in patients with MK in a CK background is not clear. Patients and Methods We conducted a retrospective analysis of 1086 patients with newly diagnosed AML treated between January 1998 and December 2007. Patients received treatment with one of the institution's first-line protocols. Results Four hundred eighty-three patients had CK. Among them, 370 patients (77%) had CK-MK, and 195 patients (53%) had CK-MK-C17 abns. Patients with CK-MK had significantly shorter OS rates compared with patients with CK without MK (4.4 vs. 8 months, respectively; P =.002). The median OS for patients with CK-C17 abns was shorter than for patients without C17 abns (4 vs. 6.1 months, respectively; P =.004). In a multivariate analysis, the presence of MK among patients with CK was identified as an independent prognostic marker for OS. In addition, presence of C17 abns had a significant negative effect on OS among patients with CK-MK (P =.04). Conclusion Among patients with CK-AML, MK was associated with poor outcomes. Additional presence of C17 abns further worsens the outcome in these particularly poor-risk patients with AML.

AB - Background Chromosome 17 abnormalities are associated with poor outcome in leukemias including AML. Recently, MK was introduced as an independent predictor of dismal outcome in AML. The additional prognostic effect of C17 abns in patients with MK in a CK background is not clear. Patients and Methods We conducted a retrospective analysis of 1086 patients with newly diagnosed AML treated between January 1998 and December 2007. Patients received treatment with one of the institution's first-line protocols. Results Four hundred eighty-three patients had CK. Among them, 370 patients (77%) had CK-MK, and 195 patients (53%) had CK-MK-C17 abns. Patients with CK-MK had significantly shorter OS rates compared with patients with CK without MK (4.4 vs. 8 months, respectively; P =.002). The median OS for patients with CK-C17 abns was shorter than for patients without C17 abns (4 vs. 6.1 months, respectively; P =.004). In a multivariate analysis, the presence of MK among patients with CK was identified as an independent prognostic marker for OS. In addition, presence of C17 abns had a significant negative effect on OS among patients with CK-MK (P =.04). Conclusion Among patients with CK-AML, MK was associated with poor outcomes. Additional presence of C17 abns further worsens the outcome in these particularly poor-risk patients with AML.

KW - AML

KW - Chromosome 17 abnormalities

KW - Complex karyotype

KW - Monosomal karyotype

UR - http://www.scopus.com/inward/record.url?scp=84896400386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896400386&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2013.07.009

DO - 10.1016/j.clml.2013.07.009

M3 - Article

C2 - 24461514

AN - SCOPUS:84896400386

VL - 14

SP - 163

EP - 171

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2650

IS - 2

ER -